InfuSystem Holdings, Inc (INFU) stock
Close on Nov 17, 2026Market cap $294.58MP/E 36.1Yield –
Earnings
InfuSystem's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of InfuSystem's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 23, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026before the open | $37.60M | +3.0% | $0.15 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 4, 2026before the open | $36.90M | +2.5% | $0.15 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026before the open | $33.70M | -2.9% | $0.05 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 24, 2026before the open | $36.20M | +7.1% | $0.10 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 4, 2025before the open | $36.50M | +3.4% | $0.11 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 5, 2025before the open | $36.00M | +6.8% | $0.12 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025before the open | $34.70M | +8.4% | -$0.01 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 4, 2025before the open | $33.80M | +6.3% | $0.04 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024before the open | $35.30M | +10.7% | $0.08 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024before the open | $33.70M | +6.3% | $0.03 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024before the open | $32.00M | +5.3% | -$0.05 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 14, 2024before the open | $31.80M | +10.4% | $0.00 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 7, 2023before the open | $31.90M | +16.8% | $0.03 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023before the open | $31.70M | – | $0.02 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 4, 2023before the open | $30.40M | +13.4% | -$0.02 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 15, 2023before the open | $28.80M | – | $0.01 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022before the open | $27.30M | +2.6% | $0.02 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022before the open | $26.80M | – | -$0.02 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 15, 2021before the open | $26.60M | – | -$0.02 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 12, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 17, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 12, 2020before the open | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 13, 2020before the open | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | May 14, 2020before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
InfuSystem's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| pro-forma net revenue growthnon-GAAP | FY2026 | +6% – +8% | – | New | Nov 5, 2026 |
| pro-forma net revenue growthnon-GAAP | FY2026 | +6% – +8% | +6% – +8% | Reaffirmed | Aug 4, 2026 |
Guidance vs results
The last range InfuSystem gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue growth | +6% – +8% | +6.38%Σ4Q | Within range |
Guidance history
Every forecast InfuSystem put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 5, 2026 | pro-forma net revenue growth | FY2026 | +6% – +8% | New |
| Aug 4, 2026 | pro-forma net revenue growth | FY2026 | +6% – +8% | Reaffirmed |
| May 7, 2026 | pro-forma net revenue growth | FY2026 | +6% – +8% | New |
| Nov 4, 2025 | Adjusted EBITDA margin (non-GAAP) | FY2025 | 20% | New |
| Nov 4, 2025 | net revenue growth | FY2025 | +6% – +8% | New |
| Aug 5, 2025 | Adjusted EBITDA margin | FY2025 | 20% | New |
| Aug 5, 2025 | net revenue growth | FY2025 | +6% – +8% | Lowered |
| May 8, 2025 | net revenue growth | FY2025 | +8% – +10% | Reaffirmed |
| Mar 4, 2025 | net revenue growth | FY2025 | +8% – +10% | New |
| Nov 7, 2023 | Adjusted EBITDA margin (non-GAAP) | FY2023 | 17% – 18% | New |
| Nov 7, 2023 | net revenue growth | FY2023 | +11% | New |
| Aug 3, 2023 | Adjusted EBITDA margin (non-GAAP) | FY2023 | 17% – 18% | Lowered |
| May 4, 2023 | Adjusted EBITDA | FY2023 | $22.00M | Reaffirmed |
| May 4, 2023 | Adjusted EBITDA margin (non-GAAP) | FY2023 | 19% | Reaffirmed |
| May 4, 2023 | net revenues | FY2023 | $118.00M – $121.00M | Reaffirmed |
| Mar 15, 2023 | Adjusted EBITDA | FY2023 | $22.00M | New |
| Mar 15, 2023 | Adjusted EBITDA margin (non-GAAP) | FY2023 | 19% | New |
| Mar 15, 2023 | net revenue growth | FY2023 | +8% – +10% | New |
| Mar 15, 2023 | net revenues | FY2023 | $118.00M – $121.00M | New |
| Nov 8, 2022 | Adjusted EBITDA | FY2022 | $22.00M | Lowered |
| Nov 8, 2022 | Adjusted EBITDA margin | FY2022 | 19% – 20% | Lowered |
| Nov 8, 2022 | total revenue | FY2022 | $112.00M | New |
| May 5, 2022 | Adjusted EBITDA | FY2022 | $24.00M – $27.00M | New |
| May 5, 2022 | Adjusted EBITDA margin | FY2022 | 20% – 22% | New |
| May 5, 2022 | net revenue growth | FY2022 | +15% – +20% | New |
| May 5, 2022 | net revenues | FY2022 | $118.00M – $123.00M | New |
| Nov 15, 2021 | Adjusted EBITDA | FY2021 | $27.00M – $28.00M | New |
| Nov 15, 2021 | Adjusted EBITDA margin | FY2021 | 25% | New |
| Nov 15, 2021 | operating cash flow | FY2021 | $19.00M – $22.00M | New |
| Nov 15, 2021 | investing cash flows | FY2021 | $12.00M – $15.00M | Lowered |
| Nov 15, 2021 | combined Pain Management and Wound Care revenues | Q4 FY2021 | $15.00M | New |
| Nov 15, 2021 | net revenues | FY2021 | $107.00M – $110.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases InfuSystem filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Update
- Update
- Update
- Update
- Results
- Update
- Update
- Results
- Update
- Update
- Update
- Results
- Update
See a number that looks wrong?